GSK Expand its 2020 Collaboration with Vir to Advance New Therapies for Influenza and Other Respiratory Viruses

 GSK Expand its 2020 Collaboration with Vir to Advance New Therapies for Influenza and Other Respiratory Viruses

GSK Expand its 2020 Collaboration with Vir to Advance New Therapies for Influenza and Other Respiratory Viruses

Shots:

  • Vir will receive ~$225M up front, $120M as an equity investment and $200M as regulatory milestones, ~300M as option payment and will be responsible to fund the development of VIR-2482 through the completion of the P-II trial
  • GSK to get an exclusive option to co-develop VIR-2482 after Vir completes and reports P-II trial outcomes, and will share development costs on the development of all other influenza mAbs
  • The new collaboration will engage the companies in two research programs. The first for functional genomics collaboration expanded to include respiratory viruses and others to develop up to three mAb to target non-influenza pathogens

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: FX Daily Report

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post